2023 MDA Clinical & Scientific Conference

BioSensics is excited to sponsor and attend the 2023 MDA Clinical & Scientific Conference next week in Dallas, TX (Booth #730). Also, I am pleased to give one of the talks in the "Remote Outcomes and Decentralized Studies" session on Tuesday, March 21.  As a part of this talk, I will discuss our work in using wearable sensors and digital health technologies to track disease progression in different neurological diseases and provide examples from our studies in ALS, myasthenia gravis (MG), progressive supranuclear palsy (PSP), Parkinson disease (PD) and ataxia. 

In addition, our team will present a poster titled "Remote multimodal monitoring of neuromuscular disease progression using wearable sensors and digital assessments" (Poster #69). The poster highlights our work in using 1) the PAMSys sensor for at-home monitoring of physical activity, posture, falls, and function in ALS and MG, and 2) BioDigit Home for digital speech, handwriting, and pattern tracing assessments, as well as the collection of video biomarkers in ALS and MG.

Some highlights of our work in ALS and MG are:

- In ALS, the sensor-derived measures of physical activity from the PAMSys sensor  show significant correlation with the gross motor subdomain scores of the ALSFRS-R. In addition, digital speech biomarkers show moderate to significant correlations with the bulbar subdomain scores of the ALSFRS-R. The study is in collaboration with Dr. Andrew Geronimo and Dr. Zachary Simmons (Penn State Health).

- In MG, we have developed a solution to standardize the collection of clinical questionnaires (MG-ADL and MG-QoL15r), speech data, and facial videos for remote at-home monitoring or centralized assessments during clinical/site visits. Our solution includes a state-of-art video biomarker analysis technology to measure facial characteristics and ptosis in MG. Our work in MG is supported by a $2.5M award from the NIH and in collaboration with Dr. Amanda Guidon (Massachusetts General Hospital), and MGNet, an NIH-Funded Rare Diseases Clinical Research Network Consortium. 

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now being used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. Our experienced research team provides comprehensive technical and scientific consulting including study design and protocol development support, as well as statistical analysis. In addition, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.